https://www.anavex.com/_files/ugd/79bcf7_4e15217c129541228327838b534afe4d.pdf
**Phase IIb/III ATTENTION-AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease Patients**
Pending approval in Europe by the end of 2025 with superior clinical data to all approved Alzheimer’s drugs. Still under $1B market cap with massive SI. 💎🙌
Another conference coming on Monday morning 👀